CORMEDIX INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value
CORMEDIX INC. (CRMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value of $0.00 per share for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue · last filed 2021-08-12
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, grant date intrinsic value for the quarter ending 2021-03-31 was $1757174.00.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, grant date intrinsic value for the quarter ending 2019-03-31 was $409275.00.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, grant date intrinsic value for the quarter ending 2018-03-31 was $0.00.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, grant date intrinsic value for fiscal 2020 was $2585172.00, a 1549.30% increase from fiscal 2019.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, grant date intrinsic value for fiscal 2019 was $156744.00, a 72.63% decline from fiscal 2018.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, grants in period, grant date intrinsic value for fiscal 2018 was $572610.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value 12 month |
|---|---|---|---|---|
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | $1757174.00 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $2585172.00 10-K · filed 2021-03-30 | |||
| 2020-09-30 | $1070717.00 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $1132914.00 10-Q · filed 2020-08-10 | |||
| 2019-12-31 | $156744.00 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $82824.00 10-Q · filed 2019-11-14 | |||
| 2019-06-30 | $374061.00 10-Q · filed 2019-08-14 | |||
| 2019-03-31 | $409275.00 10-Q · filed 2019-05-13 | |||
| 2018-12-31 | $572610.00 10-K · filed 2019-05-29 | |||
| 2018-09-30 | $360150.00 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | $500.00 10-Q · filed 2018-08-14 | |||
| 2018-03-31 | $0.00 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |